{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:06:29Z","timestamp":1789473989081,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Greifswald"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The endpoint Time to Subsequent Therapy (TTST) is an intermediate endpoint used in research and regulatory assessments. TTST denotes initiation of subsequent therapy and is a clearly definable, clinically relevant event for healthcare professionals. However, it has not been systematically established to which extent TTST is subjectively meaningful to patients. The objective of this study was to define TTST as a patient-relevant intermediate endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study examined five oncological indications (breast cancer, prostate cancer, melanoma, multiple myeloma, and non-small cell lung cancer) using a systematic literature review, analysis of case report forms used in international randomized controlled trials, review of German Federal Joint Committee (G-BA) documents, semi-structured interviews and a two-stage Delphi survey with healthcare professionals, patients, and relatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 35 individuals participated in qualitative interviews. Most of them rated TTST as particularly significant. The Delphi Survey included 264 interviewees in round one, and 117 in round two. Patient-relevance of TTST was confirmed by 81% of respondents (95% confidence interval 76%, 85%). Nine treatment scenarios that justify TTST were identified. To capture patient-relevance, prospective collection of reasons for and consequences of therapy change are required. A checklist with standardized response formats plus free-text fields was developed: a comprehensive master checklist for flexible, complete documentation and a short version focused on therapy change-specific items.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TTST is an intermediate endpoint whose systematic documentation of characteristics demonstrating patient-relevance can be standardized in research and clinical practice using the developed checklists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06583-w","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:33:11Z","timestamp":1788359591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time to subsequent therapy (TTST) as an endpoint in clinical studies: development of standardized documentation of subsequent therapy through systematic literature review, expert interviews, and Delphi survey"],"prefix":"10.1007","volume":"152","author":[{"given":"Bianca","family":"Biedenweg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5956-8309","authenticated-orcid":false,"given":"Thomas","family":"Kohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Danner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mehnert-Theuerkauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Filippig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Ziemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Osowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2297-3366","authenticated-orcid":false,"given":"Peter","family":"Kaskel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"23","key":"6583_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.2217\/fon-2022-0616","volume":"19","author":"P Agapow","year":"2023","unstructured":"Agapow P, Mulla R, Markuzon N, Ottesen LH, Meulendijks D (2023) Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors. Future Oncol 19(23):1627\u20131639. https:\/\/doi.org\/10.2217\/fon-2022-0616","journal-title":"Future Oncol"},{"key":"6583_CR2","unstructured":"AMNOG-Monitor 2025. https:\/\/www.amnog-monitor.com\/de. Accessed 29 Apr 2025"},{"issue":"7","key":"6583_CR3","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","volume":"34","author":"NJ Bahlis","year":"2020","unstructured":"Bahlis NJ, Nizar JB, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J (2020) Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 34(7):1875\u20131884. https:\/\/doi.org\/10.1038\/s41375-020-0711-6","journal-title":"Leukemia"},{"key":"6583_CR4","doi-asserted-by":"crossref","unstructured":"Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3): 89\u201395 [This is the original reference quoted in IQWiG methods 4.0 as of April-22nd, 2015 when definition of patient relevance was added. Early-benefit-assessment in Germany is conducted by IQWiG as commissioned by the Federal Joint Committee [G-BA], or G-BA itself for orphan drugs)","DOI":"10.1067\/mcp.2001.113989"},{"issue":"1","key":"6583_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100340","volume":"7","author":"S Branchoux","year":"2022","unstructured":"Branchoux S, Sofeu L, Gaudin A-F, Kurt M, Moshyk A, Italiano A, Bellera C, Rondeau V (2022) Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial. ESMO Open 7(1):100340. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100340","journal-title":"ESMO Open"},{"key":"6583_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082311","volume":"12","author":"BA Campbell","year":"2020","unstructured":"Campbell BA, Scarisbrick JJ, Kim YH, Wilcox RA, McCormack C, Prince HM (2020) Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma. Cancers 12:2311","journal-title":"Cancers"},{"key":"6583_CR7","unstructured":"Cancer Information Service. Addresses and Links Self-help Groups. https:\/\/www.krebsinformationsdienst.de\/adressen-und-links\/selbsthilfegruppen"},{"issue":"11","key":"6583_CR8","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S2352-3026(17)30168-0","volume":"4","author":"AA Chanan-Khan","year":"2017","unstructured":"Chanan-Khan AA, Zaritskey A, Egyed M, Vokurka S, Semochkin S, Schuh A, Kassis J, Simpson D, Zhang J, Purse B, Fo\u00e0 R (2017) Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 4(11):e534\u2013e543. https:\/\/doi.org\/10.1016\/S2352-3026(17)30168-0","journal-title":"Lancet Haematol"},{"key":"6583_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2191-1991-4-2","volume":"4","author":"I Dabisch","year":"2014","unstructured":"Dabisch I, Dethling J, Dintsios CM, Drechsler M, Kalanovic D, Kaskel P, Langer F, Ruof J, Ruppert T, Wirth D (2014) Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany. Health Econ Rev 4:2","journal-title":"Health Econ Rev"},{"key":"6583_CR25","unstructured":"EMA Scientific Guidelines. Guideline evaluation of anticancer medicinal products in man. Appendix 1. Methodological consideration regarding using progression free survival or disease free survival in confirmatory trials. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/appendix-1-guideline-evaluation-anticancer-medicinal-products-man-methodological-consideration-using-progression-free-survival-or-disease-free-survival-confirmatory-trials_en.pdf. Accessed 24 Jan 2025"},{"key":"6583_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-26-00226","author":"MH Fiero","year":"2026","unstructured":"Fiero MH, Shah M, Amiri-Kordestani L (2026) Is progression-free survival 2 ready for prime time in US food and drug administration regulatory decision making? J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-26-00226","journal-title":"J Clin Oncol"},{"key":"6583_CR11","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Sanz R, Oriol A, Moreno MJ, Rubia J de la, Payer AR, Hern\u00e1ndez MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abell\u00e1 E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV; Spanish Myeloma Group (GEM\/PETHEMA) (2015) Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica 100(9):1207-13. https:\/\/doi.org\/10.3324\/haematol.2015.128439","DOI":"10.3324\/haematol.2015.128439"},{"key":"6583_CR12","unstructured":"German Cancer Society. Oncomap. https:\/\/www.oncomap.de\/centers?showMap=1. Accessed 26 Oct 2025"},{"key":"6583_CR13","volume-title":"Delphi surveys","author":"M H\u00e4der","year":"2014","unstructured":"H\u00e4der M (2014) Delphi surveys. Springer Fachmedien, Wiesbaden"},{"key":"6583_CR14","unstructured":"INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE. ICH HARMONISED GUIDELINE. ADDENDUM ON ESTIMANDS AND SENSITIVITY ANALYSIS IN CLINICAL TRIALS TO THE GUIDELINE ON STATISTICAL PRINCIPLES FOR CLINICAL TRIALS. E9(R1). Final version. Adopted on 20 November 2019. https:\/\/database.ich.org\/sites\/default\/files\/E9-R1_Step4_Guideline_2019_1203.pdf. Accessed 24 Jul 2026"},{"key":"6583_CR15","unstructured":"Joint HTA Bodies with Regulatory. Joint HTAB with Regulatory Perspectives on Understanding Evidence Challenges and Managing Uncertainties and Exploring Potential Solutions. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/other\/joint-htab-regulatory-perspectives-understanding-evidence-challenges-managing-uncertainties-exploring-potential-solutions_en.pdf. Accessed 02 Jun 2025"},{"issue":"4","key":"6583_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/00004479-200610000-00007","volume":"29","author":"LE Kazis","year":"2006","unstructured":"Kazis LE, Selim A, Rogers W, Ren XS, Lee A, Miller DR (2006) Dissemination of methods and results from the veterans health study: final comments and implications for future monitoring strategies within and outside the veterans healthcare system. J Ambul Care Manage 29(4):310\u2013319. https:\/\/doi.org\/10.1097\/00004479-200610000-00007","journal-title":"J Ambul Care Manage"},{"key":"6583_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000793","author":"CM Mantia","year":"2022","unstructured":"Mantia CM, Werner L, Stwalley B, Ritchings C, Tarhini AA, Atkins MB, McDermott DF, Regan MM (2022) Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors. Melanoma Res. https:\/\/doi.org\/10.1097\/CMR.0000000000000793","journal-title":"Melanoma Res"},{"key":"6583_CR18","doi-asserted-by":"publisher","unstructured":"Mayring P (2019) Qualitative content analysis. Delimitations, variants, further developments [30 paragraphs; in German]. Forum Qualitative Sozialforschung\/Forum: Qualitative Social Research, 20(3), 16, https:\/\/doi.org\/10.17169\/fqs-20.3.3343.","DOI":"10.17169\/fqs-20.3.3343"},{"issue":"15","key":"6583_CR19","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1200\/JCO.23.0022","volume":"41","author":"M Merino","year":"2023","unstructured":"Merino M, Kasamon Y, Pazdur R, Kluetz P, Gormley N (2023) Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival. J Clin Oncol 41(15):2706\u20132712. https:\/\/doi.org\/10.1200\/JCO.23.0022","journal-title":"J Clin Oncol"},{"key":"6583_CR20","unstructured":"NN. Olaparib 2015. Federal Joint Committee: Dossier assessment for Orphan Drugs: Olaparib [https:\/\/www.g-ba.de\/downloads\/92-975-868\/2015-08-28_Nutzenbewertung%20G-BA_Olaparib.pdf. Accessed 05 Jul 2024"},{"issue":"9","key":"6583_CR21","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3109\/10428194.2015.1122783","volume":"57","author":"A \u00d6sterborg","year":"2016","unstructured":"\u00d6sterborg A, Udvardy M, Zaritskey A, Andersson P-O, Grosicki S, Mazur G, Kaplan P, Steurer M, Schuh A, Montillo M, Kryachok I, Middeke JM, Kulyaba Y, Rekhtman G, Gorczyca M, Daly S, Chang C-N, Lisby S, Gupta I (2016) Phase III, randomized study of ofatumumab versus physicians\u2019 choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 57(9):2037\u20132046. https:\/\/doi.org\/10.3109\/10428194.2015.1122783","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"6583_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Larocca A, Rossi D, Raimondo FD, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omed\u00e9 P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M (2014) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 32(7):634\u2013640. https:\/\/doi.org\/10.1200\/JCO.2013.52.0023","journal-title":"J Clin Oncol"},{"issue":"1","key":"6583_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3226-3","volume":"18","author":"R Porzig","year":"2018","unstructured":"Porzig R, Neugebauer S, Heckmann T, Adolf D, Kaskel P, Froster UG (2018) Evaluation of a cancer patient navigation program (\u201cOnkolotse\u201d) in terms of hospitalization rates, resource use and healthcare costs: rationale and design of a randomized, controlled study. BMC Health Serv Res 18(1):413. https:\/\/doi.org\/10.1186\/s12913-018-3226-3","journal-title":"BMC Health Serv Res"},{"key":"6583_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cpt.2453","volume":"111","author":"DR Rivera","year":"2022","unstructured":"Rivera DR, Henk HJ, Garrett-Mayer E, Christian JB, Belli AJ, Bruinooge SS, Espirito JL, Sweetnam C, Izano MA, Natanzon Y, Robert NJ, Walker MS, Cohen AB, Boyd M, Enewold L, Hansen E, Honnold R, Kushi L, Mishra Kalyani PS, Pe Benito R, Sakoda LC, Sharon E, Tymejczyk O, Valice E, Wagner J, Lasiter L, Allen JD (2022) The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: methodological recommendations from oncology case studies. Clin Pharmacol Ther 111:283\u2013292","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06583-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:41:46Z","timestamp":1789472506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06583-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["6583"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06583-w","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional vfa grant (TK, BB, JZ). Employment (TR-vfa; UO-MHG; PK-MSD). No conflicts (MD, AMT, DL, UF).","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed by the Ethics Committee of University Medicine Greifswald (internal register BB 090\/19) issued on July 31, 2019. The authors used AI-assisted language editing tools to translate the original German version to the English language. The manuscript was edited several times by co-authors and native speakers afterwards. The authors take full responsibility for the final content. This paper was presented in part at the European Society for Medical Oncology 2025 Annual Conference, Berlin, Germany (2366P) and German Cancer Conference 2026, Berlin, Germany (DKK2026-136).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"179"}}